| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ALGEN Stock Overview
genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide.
genOway Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.24 |
| 52 Week High | €4.87 |
| 52 Week Low | €2.64 |
| Beta | 0.33 |
| 1 Month Change | -3.43% |
| 3 Month Change | -14.87% |
| 1 Year Change | -12.57% |
| 3 Year Change | 106.05% |
| 5 Year Change | 44.42% |
| Change since IPO | -46.17% |
Recent News & Updates
We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Shareholder Returns
| ALGEN | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 7.8% | 16.0% | 3.6% |
| 1Y | -12.6% | -41.0% | -11.3% |
Return vs Industry: ALGEN exceeded the French Biotechs industry which returned -41% over the past year.
Return vs Market: ALGEN underperformed the French Market which returned -11.3% over the past year.
Price Volatility
| ALGEN volatility | |
|---|---|
| ALGEN Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.9% |
Stable Share Price: ALGEN is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALGEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 123 | Alexandre Fraichard | https://www.genoway.com |
genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines.
genOway Société anonyme Fundamentals Summary
| ALGEN fundamental statistics | |
|---|---|
| Market Cap | €28.55m |
| Earnings (TTM) | -€322.60k |
| Revenue (TTM) | €19.59m |
1.5x
P/S Ratio-88.5x
P/E RatioIs ALGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALGEN income statement (TTM) | |
|---|---|
| Revenue | €19.59m |
| Cost of Revenue | €9.39m |
| Gross Profit | €10.20m |
| Other Expenses | €10.53m |
| Earnings | -€322.60k |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 26, 2022
| Earnings per share (EPS) | -0.037 |
| Gross Margin | 52.08% |
| Net Profit Margin | -1.65% |
| Debt/Equity Ratio | 73.5% |
How did ALGEN perform over the long term?
See historical performance and comparisonValuation
Is ALGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALGEN?
Other financial metrics that can be useful for relative valuation.
| What is ALGEN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €28.55m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 78.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ALGEN's PS Ratio compare to its peers?
| ALGEN PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6x | ||
ALSEN Sensorion | 7.3x | 14.1% | €31.2m |
ERYP ERYTECH Pharma | 10.8x | 42.7% | €35.4m |
ALONC Oncodesign Société Anonyme | 1.6x | 9.7% | €57.5m |
ALPAT Plant Advanced Technologies | 4.2x | -5.6% | €18.6m |
ALGEN genOway Société anonyme | 1.5x | n/a | €28.5m |
Price-To-Sales vs Peers: ALGEN is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (6x).
Price to Earnings Ratio vs Industry
How does ALGEN's PE Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Sales vs Industry: ALGEN is good value based on its Price-To-Sales Ratio (1.5x) compared to the French Biotechs industry average (8.3x)
Price to Sales Ratio vs Fair Ratio
What is ALGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALGEN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ALGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALGEN's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALGEN's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is genOway Société anonyme forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
42.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as genOway Société anonyme has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of ALGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- genOway Société anonyme competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has genOway Société anonyme performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-59.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALGEN is currently unprofitable.
Growing Profit Margin: ALGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALGEN is unprofitable, and losses have increased over the past 5 years at a rate of 59.2% per year.
Accelerating Growth: Unable to compare ALGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: ALGEN has a negative Return on Equity (-2.19%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is genOway Société anonyme's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: ALGEN's short term assets (€19.3M) exceed its short term liabilities (€8.3M).
Long Term Liabilities: ALGEN's short term assets (€19.3M) exceed its long term liabilities (€9.7M).
Debt to Equity History and Analysis
Debt Level: ALGEN's net debt to equity ratio (35.5%) is considered satisfactory.
Reducing Debt: ALGEN's debt to equity ratio has increased from 1% to 73.5% over the past 5 years.
Debt Coverage: ALGEN's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ALGEN's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Dividend
What is genOway Société anonyme current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALGEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALGEN has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average board tenure
CEO
Alexandre Fraichard
23.42yrs
Tenure
Dr. Alexandre Fraichard, MBA, HEC, Co-Founded GenOway S.A. in 1999 and also serves as its General Manager since July 2020. Dr. Fraichard served as Chief operating Officer at GenOway S.A. since May 2019. He...
Board Members
Experienced Board: ALGEN's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.
Top Shareholders
Company Information
genOway Société anonyme's employee growth, exchange listings and data sources
Key Information
- Name: genOway Société anonyme
- Ticker: ALGEN
- Exchange: ENXTPA
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €28.545m
- Shares outstanding: 8.82m
- Website: https://www.genoway.com
Number of Employees
Location
- genOway Société anonyme
- Technopark 2
- 31 Rue Saint Jean-de-Dieu
- Lyon
- Rhône-Alpes
- 69007
- France
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/26 00:00 |
| End of Day Share Price | 2022/06/24 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.